Patents Assigned to Genentech, Inc.
  • Publication number: 20240132612
    Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Application
    Filed: April 20, 2023
    Publication date: April 25, 2024
    Applicant: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Patent number: 11963994
    Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: April 23, 2024
    Assignee: Genentech, Inc.
    Inventors: Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
  • Patent number: 11967072
    Abstract: The present disclosure relates to techniques for segmenting objects within medical images using a deep learning network that is localized with object detection based on a derived contrast mechanism. Particularly, aspects are directed to localizing an object of interest within a first medical image having a first characteristic, projecting a bounding box or segmentation mask of the object of interest onto a second medical image having a second characteristic to define a portion of the second medical image, and inputting the portion of the second medical image into a deep learning model that is constructed as a detector using a weighted loss function capable of segmenting the portion of the second medical image and generating a segmentation boundary around the object of interest. The segmentation boundary may be used to calculate a volume of the object of interest for determining a diagnosis and/or a prognosis of a subject.
    Type: Grant
    Filed: February 7, 2022
    Date of Patent: April 23, 2024
    Assignee: Genentech, Inc.
    Inventors: Luke Xie, Kai Henrik Barck, Omid Bazgir
  • Publication number: 20240129306
    Abstract: The present disclosure relates to techniques for service to service communication and authentication via a network mesh. Particularly, aspects are directed to receiving, at a network mesh, a service request for a first service, and obtaining information associated with the first service. The information includes a location of a first pod encapsulating the first service. The network mesh using the location of the first pod, retrieves security rules specific for the first pod. The network mesh forwards the service request to the first service based on the security rules of the first pod and obtains results of the service request from the first service. The results include a sub result obtained from a second service in accordance with security rules for the first pod encapsulating the first service and security rules for a second pod encapsulating the second service.
    Type: Application
    Filed: May 4, 2023
    Publication date: April 18, 2024
    Applicant: Genentech, Inc.
    Inventors: Niaz Ahsan Jalal, Abdesslem Dride
  • Publication number: 20240123066
    Abstract: The present disclosure provides liquid formulations comprising polypeptides and surfactants. In particular, it discloses a liquid formulation comprising a polypeptide and a surfactant, wherein at least about 70% (wt %) of the surfactant are isosorbide polyoxyethylene (POE) fatty acid esters. The invention also provides methods for making such liquid formulations, articles of manufacture comprising such liquid formulations and methods of treating a patient with such liquid formulations.
    Type: Application
    Filed: December 6, 2023
    Publication date: April 18, 2024
    Applicant: Genentech, Inc.
    Inventors: Anthony TOMLINSON, Barthelemy Luc DEMEULE, Isidro Angelo Eleazar ZARRAGA
  • Publication number: 20240127957
    Abstract: Techniques disclosed herein relate to inferring a type of multiple sclerosis and determining whether to output an alert based on codes detected within noisy assessment data corresponding to a subject. The noisy assessment data includes content originating from a care provider that identifies a characteristic of the subject or of a treatment for the subject, and the subject has been diagnosed with multiple sclerosis. A temporal dynamic or distribution is determined based on instances of the code detection, and a modulation is determined based on the temporal dynamic or the distribution. It is determined whether an alert criterion is satisfied based on whether the modulation is above a threshold so as to represent noise or a predicted transition across types of multiple sclerosis. The inferred type of multiple sclerosis is output. When the alert criterion is satisfied, an alert is output as well.
    Type: Application
    Filed: November 10, 2023
    Publication date: April 18, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.
    Inventors: Shemra Rizzo, Kelly Anne Zalocusky, Katherine Anne Belendiuk, Nicole Gidaya Bonine, Yifeng Chia, Laura Gaetano, Ryan William Gan, Jumaah Ingram Goldberg, Xiaoming Jia
  • Publication number: 20240124603
    Abstract: The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.
    Type: Application
    Filed: August 17, 2023
    Publication date: April 18, 2024
    Applicant: Genentech, Inc.
    Inventors: Craig SMITH, Peter S. CHIN
  • Patent number: 11958906
    Abstract: The disclosure provides pharmaceutical compositions comprising mosunetuzumab and methods of using the same.
    Type: Grant
    Filed: April 13, 2023
    Date of Patent: April 16, 2024
    Assignee: Genentech, Inc.
    Inventors: Junyan A. Ji, Jacqueline Yvonne Tyler
  • Publication number: 20240116872
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: October 18, 2023
    Publication date: April 11, 2024
    Applicants: GENENTECH, INC., CURIS, INC
    Inventors: Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
  • Publication number: 20240115555
    Abstract: Provided herein are therapies including dosage regimens for the treatment of cancer using B-RAF and an immune checkpoint inhibitor in combination with and/or without a MEK inhibitor.
    Type: Application
    Filed: December 18, 2023
    Publication date: April 11, 2024
    Applicant: Genentech, Inc.
    Inventors: Dawn Colburn, Nicole Richie
  • Publication number: 20240115718
    Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma “DLBCL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an immunomodulatory agent (such as lenalidomide) and an anti-CD20 antibody (such as obinutuzumab or rituximab).
    Type: Application
    Filed: November 9, 2023
    Publication date: April 11, 2024
    Applicant: Genentech, Inc.
    Inventors: Jamie Harue HIRATA, Lisa Linnea MUSICK
  • Publication number: 20240108616
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: November 10, 2023
    Publication date: April 4, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Publication number: 20240110909
    Abstract: Methods are provided to rapidly and accurately detect, characterize, measure, and quantify site-specific antibody drug conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.
    Type: Application
    Filed: November 20, 2023
    Publication date: April 4, 2024
    Applicant: Genentech, Inc.
    Inventors: Martine Darwish, Surinder Kaur, Dian Su, Keyang Xu
  • Publication number: 20240109958
    Abstract: Provided herein are antibodies that bind to a peptide of an N-terminally ubiquitinated polypeptide and methods of screening for such antibodies. Also provided herein are detection and enrichment methods using such antibodies for detecting or enriching a peptide of an N-terminally ubiquitinated polypeptide.
    Type: Application
    Filed: December 12, 2023
    Publication date: April 4, 2024
    Applicant: Genentech, Inc.
    Inventors: Donald Scott KIRKPATRICK, James Thomas KOERBER, Christopher Williamson DAVIES
  • Patent number: 11945837
    Abstract: Methods of enhancing efficiency of downstream chromatography steps for purification of proteins comprising: (a) passing a composition comprising a polypeptide of interest and various contaminants through an ion exchange membrane, wherein the polypeptide and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pi of the polypeptide to enhance the charge of the polypeptide and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the polypeptide and at least one contaminant, (b) overloading the ion exchange membrane such that at least one contaminant remains bound to the membrane while the polypeptide of interest is primarily in the effluent; (c) collecting the effluent from the ion exchange membrane comprising the polypeptide of interest; (d) subjecting the membrane effluent comprising the polypeptide of interest to a purification step of similar charge as the previous membrane,
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: April 2, 2024
    Assignee: Genentech, Inc.
    Inventors: Jerome Joseph Bill, Jr., Arick Michael Brown, Christopher John Dowd, Brooke Ellen Thayer
  • Patent number: 11944606
    Abstract: Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: April 2, 2024
    Assignee: Genentech, Inc.
    Inventors: Timothy Heffron, Sushant Malhotra, BinQing Wei, Bryan Chan, Lewis Gazzard, Emanuela Gancia, Michael Lainchbury, Andrew Madin, Eileen Seward, Yonghan Hu
  • Publication number: 20240105283
    Abstract: A machine-learning model (e.g., a clustering model) may be used to predict a phenotype of a tumor based on expression levels of a set of genes. The set of genes may have been identified using a same or different machine-learning model. The phenotype may include an immune-excluded, immune-desert or an inflamed/infiltrated phenotype. A treatment strategy and/or treatment recommendation may be identified based on the predicted phenotype.
    Type: Application
    Filed: December 8, 2023
    Publication date: March 28, 2024
    Applicant: Genentech, Inc.
    Inventors: Akshata Ramrao Udyavar, Yulei Wang, Cleopatra Kozlowski
  • Publication number: 20240101708
    Abstract: The present disclosure relates to a multispecific antibody platform for targeted degradation of cell surface proteins. The disclosure relates to multispecific (e.g., bispecific or trispecific) binding molecules such as multispecific antibodies that target at least one transmembrane E3 ubiquitin ligase protein and at least one cell surface protein, for example, a cell surface protein that is intended for degradation, and methods of using the same.
    Type: Application
    Filed: August 1, 2023
    Publication date: March 28, 2024
    Applicant: Genentech Inc.
    Inventors: Nicholas John Agard, Felipe de Sousa e Melo, Jing Li, Hadir Mohamed Gehad Mohamed Fouad Elsayed Marei, Wen-Ting K. Tsai, Frederic Joseph De Sauvage, Jieyan He, Yee Seir Kee
  • Patent number: 11938189
    Abstract: The present invention relates to use of certain alkylglycoside compositions for the prevention of aggregation and oxidation of antibodies and other proteins in therapeutically useful formulations thereof.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: March 26, 2024
    Assignee: Genentech, Inc
    Inventors: Osigwe Esue, Vikas K. Sharma
  • Patent number: 11939559
    Abstract: An apparatus and method to maintain pH within a range conducive for cell growth in a bicarbonate-containing cell culture system without the addition of base. The method relies on the gas transfer characteristics of the bioreactor system to modulate the CO2 transfer to and from the cell culture such that the pH of the cell culture can be maintained within a desired range.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: March 26, 2024
    Assignee: GENENTECH, INC.
    Inventors: Dinesh Baskar, Jenny Hsiung, Woon-Lam Susan Leung, Inn H. Yuk